Genentech, Inc. DNA - Genentech/Novartis Ophthalmics' Lucentis will Dominate the Market
Genentech/Novartis Ophthalmics' Lucentis will Dominate the Market to Treat Wet Age-Related Macular Degeneration
Increase in the Aging Population and Earlier Awareness Will Help Triple
Drug Treatment Rates, According to a New Report from Decision Resources
Decision Resources, Inc., one of
the world's leading research and advisory firms for pharmaceutical and
healthcare issues, finds that Genentech/Novartis Ophthalmics' Lucentis
(ranibizumab), a vascular endothelial growth factor (VEGF) inhibitor, will
dominate the market and will become the new standard of care in the
treatment of wet age-related macular degeneration (AMD) by 2015.
The new Pharmacor report entitled Age-Related Macular Degeneration
finds that Lucentis will dominate the wet AMD market either as a
monotherapy or in combination with the current standard of care,
QLT/Novartis Ophthalmics' Visudyne (verteporfin/photodynamic therapy).
Lucentis will command a 52% share of the total AMD market in 2010 and a 62%
share in 2015 in the United States, Japan, France, Germany, Italy, Spain,
and the United Kingdom. The report also finds that an increasing aging
population and earlier awareness of the disease will drive a threefold
increase in the drug-treated population from 2005 to 2015.
"Additionally, more aggressive education, awareness, and screening
could significantly increase the number of patients receiving drug
treatment beyond this estimate," said Regina Cebula, analyst at Decision
Resources, Inc. "We forecast dramatic 23% annual growth in the AMD drug
treatment market from 2005 through 2010 as a result of more widespread use
of premium-priced emerging therapies, including Lucentis, as well as an
increase in the number of patients being diagnosed and treated. Thereafter,
annual market growth will level off to 8% through 2015."
About Age-Related Macular Degeneration
Age-related macular degeneration, an under-treated vision-threatening
disease affecting people over 50 years of age, will directly impact a
significant segment of the increasing aging population. Treatment of the
disease represents considerable commercial potential for developers of
innovative drug therapies. In 2005, the total prevalent population exceeded
3.8 million cases in the world's major pharmaceutical markets.
About Decision Resources
Decision Resources, Inc. (http://www.decisionresources.com) is a world
leader in market research publications, advisory services, and consulting
designed to help clients shape strategy, allocate resources, and master
their chosen markets.
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
Increase in the Aging Population and Earlier Awareness Will Help Triple
Drug Treatment Rates, According to a New Report from Decision Resources
Decision Resources, Inc., one of
the world's leading research and advisory firms for pharmaceutical and
healthcare issues, finds that Genentech/Novartis Ophthalmics' Lucentis
(ranibizumab), a vascular endothelial growth factor (VEGF) inhibitor, will
dominate the market and will become the new standard of care in the
treatment of wet age-related macular degeneration (AMD) by 2015.
The new Pharmacor report entitled Age-Related Macular Degeneration
finds that Lucentis will dominate the wet AMD market either as a
monotherapy or in combination with the current standard of care,
QLT/Novartis Ophthalmics' Visudyne (verteporfin/photodynamic therapy).
Lucentis will command a 52% share of the total AMD market in 2010 and a 62%
share in 2015 in the United States, Japan, France, Germany, Italy, Spain,
and the United Kingdom. The report also finds that an increasing aging
population and earlier awareness of the disease will drive a threefold
increase in the drug-treated population from 2005 to 2015.
"Additionally, more aggressive education, awareness, and screening
could significantly increase the number of patients receiving drug
treatment beyond this estimate," said Regina Cebula, analyst at Decision
Resources, Inc. "We forecast dramatic 23% annual growth in the AMD drug
treatment market from 2005 through 2010 as a result of more widespread use
of premium-priced emerging therapies, including Lucentis, as well as an
increase in the number of patients being diagnosed and treated. Thereafter,
annual market growth will level off to 8% through 2015."
About Age-Related Macular Degeneration
Age-related macular degeneration, an under-treated vision-threatening
disease affecting people over 50 years of age, will directly impact a
significant segment of the increasing aging population. Treatment of the
disease represents considerable commercial potential for developers of
innovative drug therapies. In 2005, the total prevalent population exceeded
3.8 million cases in the world's major pharmaceutical markets.
About Decision Resources
Decision Resources, Inc. (http://www.decisionresources.com) is a world
leader in market research publications, advisory services, and consulting
designed to help clients shape strategy, allocate resources, and master
their chosen markets.
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
posted by Bill Austin - Genentech, Inc. DNA - Genentech/Novartis Ophthalmics' Lucentis will Dominate the Market
0 Comments:
Post a Comment
Links to this post:
Create a Link
<< Home